Abstract::Allergic Rhinitis (AR) is an allergen-driven, IgE-mediated inflammatory disease of the
nasal mucosa. Established therapies are effective for many patients, but incomplete symptom
control, suboptimal adherence, and treatment preference sustain interest in new locally acting
agents. Plant-derived alkaloids are frequently proposed as anti-allergic candidates; however, the
literature often conflates natural compounds with semisynthetic derivatives and synthetic analogues
and gives similar weight to computational predictions, cell assays, animal models, and
clinical findings.
A structured critical review of chemically defined alkaloids investigated in AR was conducted.
Translational evidence was graded from Tier I (controlled human AR evidence) to Tier IV (cellular,
omics or computational evidence), while mechanistic confidence was assessed separately.
Nine canonical plant alkaloids had Tier II evidence from direct AR or combined allergic rhinitis
and asthma syndrome models with nasal outcomes: berberine, corynoline, piperine, sinomenine,
higenamine, dictamnine, ellipticine, warifteine and methylwarifteine. Reported effects included
fewer nasal symptoms, reduced mast-cell activation, lower IgE and type 2 cytokine responses, and
less eosinophilic inflammation. Warifteine and methylwarifteine constitute the most internally
coherent preclinical series; most other candidates depend on a single short-duration, ovalbuminbased
study. Randomisation, blinded outcome assessment, clinically relevant comparators, nasal
pharmacokinetics and direct target-engagement experiments were uncommon.
Safety is compound-specific and materially changes translational rank. Relevant concerns include
drug-drug interactions, non-IgE-mediated mast cell activation, systemic adrenergic effects, reactive
metabolites, and genotoxicity. Intranasal ipratropium provides controlled human evidence for
watery rhinorrhoea, but it is a purpose-designed synthetic atropine derivative and cannot validate
plant alkaloids as a therapeutic class. The available evidence therefore supports the use of selected
alkaloids as lead scaffolds and mechanistic probes, but not as established AR treatments. Progress
requires authenticated chemistry, parent- and metabolite-aware nasal exposure, causal studies in
human nasal systems, active-comparator efficacy and safety margins appropriate for long-term
treatment of a usually non-life-threatening disease.